Welcome to our dedicated page for Angle Plc news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on Angle Plc stock.
Overview of Angle Plc
Angle Plc (ANPCY) is a world-class liquid biopsy company that specializes in the innovative capture and analysis of circulating tumour cells (CTCs) from a simple blood sample. Emphasizing technical precision and validated methodologies, the company has established itself in the fields of clinical oncology, research, and pharmaceutical drug development. Using its patent-protected Parsortix system and complementary diagnostic assays, Angle Plc addresses a critical need in cancer diagnostics by enabling comprehensive downstream analysis—including whole cell imaging, proteomic, genomic, and transcriptomic analyses.
Core Technologies and Business Model
At the heart of Angle Plc's operations is the Parsortix system, an innovative cell harvesting technology designed to capture intact CTCs based on their size and deformability. This method overcomes the limitations of traditional EpCAM-based enrichment techniques by preserving the morphology and viability of harvested cells. The company has further enhanced its technology portfolio with developments such as the proprietary CellKeep slide, which significantly reduces cell loss during microscopy preparation, and specialized assays including DNA Damage Response (DDR) and Androgen Receptor detection assays.
Clinical and Research Applications
Angle Plc's technology is integral to both clinical diagnostics and research-oriented environments. Its robust system facilitates the identification and characterization of rare CTCs, thereby supporting:
- Drug Development: Custom assay development and clinical trial testing enhance the precision of targeted therapies.
- Clinical Oncology: Advanced CTC profiling offers longitudinal, minimally invasive monitoring of molecular markers tied to cancer progression and treatment response.
- Pharma Services: Strategic partnerships with major pharmaceutical companies underscore the application of the Parsortix system in assessing novel cancer therapeutics, thereby enabling more efficient patient stratification.
Market Position and Competitive Landscape
Angle Plc occupies a distinctive niche within the liquid biopsy market by combining multifunctional technologies with comprehensive clinical service offerings. While there are competitors in the broader liquid biopsy and diagnostic space, Angle Plc differentiates itself through its focus on harvesting complete, intact cells rather than fragmented DNA alone. This capability underpins their growing portfolio of peer-reviewed publications and strategic collaborations that collectively enhance the company's credibility and position in the competitive landscape.
Expertise and Technological Advancements
Deep industry expertise is evident in Angle Plc's continuous innovation in assay development and technology refinement. The company has achieved several milestones, including securing intellectual property rights in major jurisdictions and demonstrating superior performance in multiple, independent clinical studies. Its pioneering work in combining CTC analysis with next generation sequencing (NGS) further reinforces its status as a key player in the advancement of liquid biopsy technology for precision oncology.
Operational Excellence
Angle Plc operates a dual business model with a focus on both diagnostic products and custom clinical services. The diagnostic product suite emphasizes high-sensitivity, patented systems and consumables, while its clinical services include assay development and standardized testing in GCP/GCLP compliant laboratories. This integrated approach allows the company to offer comprehensive solutions to research institutions, drug developers, and clinical trial sponsors globally.
Significance in the Oncological Landscape
By enabling the detailed analysis of CTCs, Angle Plc significantly contributes to the paradigm shift towards personalized and precision medicine in oncology. Its methodologies not only increase assay sensitivity but also provide a deeper understanding of cancer biology, ultimately helping to bridge the gap between laboratory research and clinical application. The company’s commitment to extracting high-quality, actionable insights from liquid biopsy samples sets it apart as an innovator in the diagnostic field.
In Summary
Angle Plc is a testament to the evolving nature of cancer diagnostics and research. With its expertise in liquid biopsy technology, particularly in the innovative capture and analysis of circulating tumour cells, the company is well-equipped to support clinical oncology, pharmaceutical research, and drug development. Its comprehensive and continually refined portfolio of diagnostic tools and clinical services provides invaluable insights for advancing personalized cancer therapy.
ANGLE plc has announced the allotment of 500,000 new ordinary shares following the exercise of share options by Finance Director Ian Griffiths at £0.2575 each. This transaction boosts Griffiths' holdings to 1,203,832 shares, approximately 0.5% of issued share capital. Application for the shares' trading admission will be made, with an expected effective date of August 27, 2021. Post-admission, the total number of ordinary shares will be 234,848,051, which shareholders can use to calculate their interest changes under FCA regulations.
ANGLE plc announced a study from the Institute of Oncology, Slovenia that demonstrates the superior performance of its Parsortix system in harvesting circulating tumor cells (CTCs) from metastatic breast cancer patients. The study highlighted that 64% of patients yielded CTCs using Parsortix compared to 57% with an antibody-based system. The Parsortix method also preserved the morphology of 99% of the isolated cells, enhancing quality and analysis potential. This positions Parsortix for routine integration in clinical laboratories, addressing the need for non-invasive biopsy options for patients.
ANGLE plc (OTCQX:ANPCY) announced the issuance of 140,000 new ordinary shares following the exercise of employee options. The new shares will rank equally with existing shares and are set to be admitted to trading on AIM on August 12, 2021. Post-admission, the total number of ordinary shares in issue will be 234,348,051. This move is part of the company's ongoing strategy to enhance its capital structure and support its liquid biopsy technologies, which have demonstrated promising clinical results in cancer diagnostics.
ANGLE plc (OTCQX:ANPCY) has issued 26,667 new ordinary shares following the exercise of employee options, increasing the total shares to 234,208,051. The new shares will begin trading on the London Stock Exchange on 9 August 2021. ANGLE is renowned for its liquid biopsy technology, the Parsortix system, which allows non-invasive cancer cell analysis and has shown significant accuracy in clinical studies, particularly for ovarian cancer. The company is pursuing FDA clearance for its system, aiming to enhance its market position in oncology diagnostics.
ANGLE plc has secured a pharma services contract for developing two custom CTC assays targeting DNA damage repair biomarkers. The contract, valued at approximately US$ 400,000, involves developing assays for four challenging cancers: triple negative breast cancer, prostate cancer, ovarian cancer, and pancreatic cancer. The initial phase will provide significant revenue and, if successful, will lead to further clinical trials planned for H2 2022. The assays will enhance ANGLE's service offerings to pharma clients by enabling targeted analysis on circulating tumor cells.
ANGLE plc (OTCQX:ANPCY) announces significant advancements using its Parsortix system to isolate circulating tumor cells (CTCs) from patients with brain metastasis. This breakthrough offers a non-invasive alternative to traditional tissue biopsies for patients with breast cancer, non-small cell lung cancer, and melanoma, achieving 50% CTC positivity rates in breast and NSCLC patients, outperforming previous technologies. With approximately 200,000 new brain metastasis cases in the US annually, this method could enhance personalized treatment decisions and improve patient outcomes.
ANGLE plc announces the allotment of 1,023,826 new ordinary shares following the exercise of options by CEO Andrew Newland. The shares were sold at 125 pence each for personal financial reasons. After the sale, Newland retains 7,054,686 shares, equating to 3.0% of the total issued share capital, alongside options for an additional 3,000,000 shares and up to 5,400,000 through performance plans. The total number of shares in issue will rise to 234,181,384 upon the new shares' admission on July 14, 2021.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a leader in liquid biopsy technology, has issued 48,333 new Ordinary shares due to employee option exercises. This issuance increases the total shares to 233,157,558, enhancing voting rights. The shares are expected to be admitted to trading on the London Stock Exchange on July 7, 2021. ANGLE's Parsortix technology continues to gain traction, with ongoing FDA submission for CTC analysis in breast cancer and strong clinical performance in ovarian cancer diagnostics.
ANGLE plc announced the results of its Annual General Meeting held on June 30, 2021, where all resolutions were passed. The company, known for its innovative liquid biopsy technology, is progressing with the Parsortix system, which has received CE Mark approval in Europe and is awaiting FDA clearance in the U.S. for metastatic breast cancer applications. ANGLE's ongoing clinical studies show promising results, including a recent ovarian cancer test with an accuracy rate of 95.1%. Their technology aims to enhance cancer diagnostics through non-invasive methods.
ANGLE plc (AIM:AGL OTCQX:ANPCY) announces its Annual General Meeting (AGM) will take place on June 30, 2021, at 2:00 PM in Guildford, UK, as a closed meeting due to COVID-19 restrictions. Only two shareholders are required for a quorum, with executive members attending in person and others remotely. Voting will be online via proxy, and shareholders must register in advance to attend online. A business update will follow the AGM, and questions can be submitted to the Board in advance. The Annual Report was distributed to shareholders on June 4, 2021.
FAQ
What is the current stock price of Angle Plc (ANPCY)?
What is the market cap of Angle Plc (ANPCY)?
What is Angle Plc's primary area of expertise?
How does the Parsortix system work?
What are the main products and services offered by Angle Plc?
How does Angle Plc differentiate itself from competitors?
What role do innovations like the CellKeep slide play in their technology?
How are Angle Plc’s technologies applied in the clinical setting?
What significance do Angle Plc’s partnerships hold?
